Kenneth S. Guerra

Will 2023 Be The Year Of § 112 At The Supreme Court?

Withheld Prior Art And Inconsistent Arguments Used To Obtain FDA Approval Renders Patent Unenforceable

Conflicting Prosecution Statements Can Render Claims Indefinite

Claim Construction And Prosecution History Estoppel Require Viewing Patent And Prosecution History As A Whole

FDA Draft Guidance On Drug-Drug Interaction Assessment For Therapeutic Proteins

Federal Circuit Holds Time Bar Challenges Not Raised At PTAB Are Waived

FDA Draft Guidance On Licensure Of Biosimilars And Interchangeable Biosimilars For Fewer Than All Conditions Of Use For Which The Reference Product Has Been Licensed

Federal Circuit Holds § 285 Applies To Exceptional Cases, Not Exceptional Portions Of Cases